Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

PaperCitations, authors & open-access status

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 336 citations, 2023 year and bronze oa status.

336
Citations
2023
Year
bronze
OA Status

Related on ScholarIQ

Oliver Findl
Author
Steven D. Schwartz
Author
Fabrizio Giansanti
Author
The Lancet
Journal
Retinal Diseases and Treatments
Topic
Retinal Diseases and Treatments
Topic
470M+ articles · free account